DOCSLIB.ORG

King Pharmaceuticals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
King Pharmaceuticals SECURITIES AND EXCHANGE COMMISSION FORM 8-K Current report filing Filing Date: 2003-04-16 | Period of Report: 2003-04-15 SEC Accession No. 0000950144-03-005010 (HTML Version on secdatabase.com) FILER KING PHARMACEUTICALS INC Mailing Address Business Address 501 FIFTH ST 501 FIFTH ST CIK:1047699| IRS No.: 541684963 | State of Incorp.:TN | Fiscal Year End: 1231 BRISTOL TN 37620 BRISTOL TN 37620 Type: 8-K | Act: 34 | File No.: 001-15875 | Film No.: 03651444 4239898000 SIC: 2834 Pharmaceutical preparations Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2003 KING PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Tennessee 0-24425 54-1684963 (State or Other Jurisdiction of (Commission (I.R.S. Employer Incorporation or Organization) File Number) Identification Number) 501 Fifth Street, Bristol, Tennessee 37620 (Address of Principal Executive (Zip Code) Offices) Registrants telephone number, including area code: (423) 989-8000 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document TABLE OF CONTENTS SIGNATURES EXHIBIT INDEX EX-99.1 UNAUDITED CONSOLIDATED FINANCIAL STATEMENT Press Release Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents Item 5. Other Events. As announced on March 11, 2003, King received a letter from the SEC with respect to an SEC investigation of King. The letter was accompanied by a subpoena requesting the production of documents. In light of the SEC investigation and as recommended by Kings management, the audit committee of Kings Board of Directors initiated its own related internal review and retained independent counsel, who retained an independent accounting firm, to assist the audit committee. On March 31, 2003, because the audit committees investigation was not complete and no conclusions had been reached, King filed a Form 12b-25 with the SEC to obtain a 15-day extension for filing its Form 10-K in order to provide the audit committee and its independent legal counsel with additional time to conduct a more thorough review. That review is continuing. The financial statements included in this filing are the unaudited financial statements of the Company for the year ended December 31, 2002. There can be no assurance that the audited consolidated financial statements, once issued, will not contain material changes from the unaudited consolidated financial statements filed herewith. The information filed herewith does not include the report of PricewaterhouseCoopers, the Companys independent auditor, as the financial statements filed are unaudited consolidated financial statements. Additionally, the information filed herewith does not contain disclosure on controls and procedures, the Sections 302 and 906 certifications currently required to be included in report on Form 10-K or any accompanying exhibits. Item 7. Financial Statements, Pro Forma Financial Information and Exhibits. (c) Exhibits. Exhibits required by Item 601 of Regulation S-K are incorporated herein by reference and are listed on the attached Exhibit Index of this Current Report on Form 8-K. 1 Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KING PHARMACEUTICALS, INC. Dated: April 15, 2003 By: /s/ Jefferson J. Gregory Jefferson J. Gregory, Chief Executive Officer 2 Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document Table of Contents EXHIBIT INDEX Exhibit No. Description 99.1 Unaudited Consolidated Financial Statements of King Pharmaceuticals, Inc. for the Year Ended December 31, 2002 and other information. 99.2 Press Release of King Pharmaceuticals, Inc. issued April 15, 2003. 3 Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document EXHIBIT 99.1 PART I ITEM 1. DESCRIPTION OF BUSINESS King Pharmaceuticals, Inc. was incorporated in the State of Tennessee in 1993. Our principal executive offices are located at 501 Fifth Street, Bristol, Tennessee 37620. Our telephone number is (423) 989-8000 and our facsimile number is (423) 274-8677. Our website is www.kingpharm.com. We have, since November 15, 2002, made available through our website our annual reports on Form 10-K, our quarterly reports on Form 10-Q, our current reports on Form 8-K and any amendments as soon as reasonably practical. Our wholly-owned subsidiaries are Monarch Pharmaceuticals, Inc.; Jones Pharma Incorporated; Meridian Medical Technologies, Inc.; Parkedale Pharmaceuticals, Inc.; King Pharmaceuticals Research and Development, Inc.; King Pharmaceuticals of Nevada, Inc.; and Monarch Pharmaceuticals Ireland Limited. King is a vertically integrated pharmaceutical company that develops manufactures, markets and sells branded prescription pharmaceutical products. By "vertically integrated," we mean that we have the capabilities of a major pharmaceutical company, including - sales and marketing, - manufacturing, - packaging, - distribution, - quality control and assurance, - regulatory affairs, and - research and development. Through a national sales force of approximately 800 individuals and marketing alliances, we market our branded pharmaceutical products to general/family practitioners, internal medicine physicians, cardiologists, endocrinologists, obstetrician/gynecologists, and hospitals across the United States and in Puerto Rico. Our primary business strategies include the acquisition of branded pharmaceutical products and increasing their sales through focused marketing and promotion and product life cycle management. By "product life cycle management," we mean, the extension of the life of a product, including seeking and gaining all necessary related governmental approvals, by such means as: - securing U.S. Food and Drug Administration ("FDA") approved new label indications, - developing and producing different strengths, - producing different package sizes, - developing new dosages, and - developing new product formulations. We acquire branded products from larger pharmaceutical companies. These companies sell products for various reasons including limiting their costs or eliminating duplicate products. Our business strategy also includes the development of new branded prescription pharmaceutical products, including new chemical entities, as well as the acquisition of compounds already in development, that provide us with strategic pipeline product opportunities. We also seek attractive company acquisitions which add products or products in development, technologies or sales and marketing capabilities to our key therapeutic areas or that otherwise complement our operations. 1 Unlike many of our competitors, we have a broad therapeutic focus that provides us with opportunities to purchase a wide variety of products. In addition, we have well known products in all of our therapeutic categories that Copyright © 2012 www.secdatabase.com. All Rights Reserved. Please Consider the Environment Before Printing This Document generate high prescription volumes. Our branded pharmaceutical products can be divided primarily into five therapeutic areas: - cardiovascular (including Altace(R), Corzide(R), Procanbid(R) and Thalitone(R)), - endocrinology/women's health (including Levoxyl(R), Cytomel(R), Triostat(R), Prefest(R), Menest(R), Delestrogen(R) and Nordette(R)), - anti-infectives (including Lorabid(R), Cortisporin(R), Neosporin(R), Bicillin(R) and Coly-Mycin M(R)), - critical care (including Thrombin-JMI(R), Brevital(R) and Synercid(R)), and - respiratory (including Intal(R) and Tilade(R)). We acquired from Glaxo Wellcome, Inc., predecessor to GlaxoSmithKline, for $54.0 million, including $3.1 million of assumed liabilities, all rights to the Cortisporin(R) product line in March 1997, the Viroptic(R) product line in May 1997 and six additional branded products, including Septra(R), and exclusive licenses, free of royalty obligations, for the prescription formulations of Neosporin(R) and Polysporin(R) in November 1997. In February 1998, we acquired from Warner-Lambert Company (predecessor to Pfizer), 15 branded pharmaceutical products, the Parkedale facility located in Rochester, Michigan and certain manufacturing contracts for third parties for $127.9 million, including $2.9 million of assumed liabilities. In December 1998, we acquired from Hoechst Marion Roussel, Inc. (predecessor to Aventis Pharmaceuticals, Inc.), for $362.5 million, the United States and Puerto Rico rights to Altace(R) and two other small branded pharmaceutical products. Altace(R) is an Angiotensin Converting Enzyme inhibitor, which we refer to in this report as an "ACE" inhibitor. We refer to this acquisition in this report
Load more

Recommended publications
  • Appendix a 2016 Financial Report Financial Review Pfizer Inc
    Appendix A 2016 Financial Report Financial Review Pfizer Inc. and Subsidiary Companies GLOSSARY OF DEFINED TERMS Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this 2016 Financial Report (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this 2016 Financial Report, most of which are explained or defined below: 2016 Financial Report This Financial Report for the fiscal year ended December 31, 2016, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2016 2016 Form 10-K Annual Report on Form 10-K for the fiscal year ended December 31, 2016 AAV Adeno-Associated Virus ABO Accumulated postretirement benefit obligation ACA (Also referred to as U.S. U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Healthcare Legislation) Act. ACIP Advisory Committee on Immunization Practices ALK anaplastic lymphoma kinase Allergan Allergan plc Alliance revenues Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us AM-Pharma AM-Pharma B.V. Anacor Anacor Pharmaceuticals, Inc. Astellas Astellas Pharma U.S. Inc. ASU Accounting Standards Update ATM-AVI aztreonam-avibactam Bamboo Bamboo Therapeutics, Inc. Baxter Baxter International Inc. BMS Bristol-Myers Squibb Company CDC U.S. Centers for Disease Control and Prevention Cellectis Cellectis SA Celltrion Celltrion Inc. and Celltrion Healthcare,
    [Show full text]
  • [Docket No. FDA-2017-N-3203] Wyeth Pharmaceutical
    This document is scheduled to be published in the Federal Register on 06/21/2017 and available online at https://federalregister.gov/d/2017-12908, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2017-N-3203] Wyeth Pharmaceuticals Inc. et al.; Withdrawal of Approval of 121 New Drug Applications and 161 Abbreviated New Drug Applications AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 121 new drug applications (NDAs) and 161 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. DATES: The withdrawal is effective on [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601. SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling. 2 Table 1 Application No.
    [Show full text]
  • 1 United States District Court for the Southern District
    Case 1:07-cv-12141-PBS Document 18-3 Filed 11/28/07 Page 1 of 167 UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF IOWA, CENTRAL DIVISION THE STATE OF IOWA, Plaintiff, v. ABBOTT LABORATORIES, INC., AGOURON PHARMACEUTICALS, INC., JURY TRIAL REQUESTED ALPHARMA, INC., ALZA CORPORATION, AMGEN, INC., ASTRAZENECA L.P., ASTRAZENECA PHARMACEUTICALS, LP., AVENTIS BEHRING L.L.C., COMPLAINT BARR LABORATORIES, INC., BAXTER INTERNATIONAL, INC., BAXTER HEALTHCARE CORPORATION, BAYER CORPORATION, BAYER PHARMACEUTICALS CORPORATION, BEN VENUE LABORATORIES, INC., BOEHRINGER INGELHEIM CORPORATION, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC., BRISTOL-MYERS SQUIBB COMPANY, CENTOCOR, INC., CHIRON CORPORATION, DERMIK LABORATORIES, INC., DEY, INC., DEY, L.P., ELI LILLY AND COMPANY, EMD, INC., ENDO PHARMACEUTICALS, INC., ETHEX CORPORATION, ETHICON, INC., FOREST LABORATORIES, INC., FOREST PHARMACEUTICALS, INC. GENEVA PHARMACEUTICALS, GLAXOSMITHKLINE, PLC, GLAXOWELLCOME, INC., GREENSTONE, LTD., HOECHEST MARION ROIUSSEL, INC., HOFFMAN-LAROCHE, INC., 1 Case 1:07-cv-12141-PBS Document 18-3 Filed 11/28/07 Page 2 of 167 IMMUNEX CORPORATION, IVAX CORPORATION, IVAX PHARMACEUTICALS, INC., JANSSEN PHARMACEUTICA PRODUCTS, LP, JOHNSON & JOHNSON, KING PHARMACEUTICALS, INC., KING RESEARCH AND DEVELOPMENT, MCNEIL-PPC, INC., MEDIMMUNE, INC., MERCK & CO., INC., MONARCH PHARMACEUTICALS, INC., MYLAN LABORATORIES, INC., MYLAN PHARMACEUTICALS, INC., NOVARTIS PHARMACEUTICALS CORPORATION, NOVOPHARM USA, INC., ONCOLOGY THERAPEUTICS NETWORK CORP., ORTHO-MCNEIL PHARMACEUTICAL, INC.,
    [Show full text]
  • Federal Register/Vol. 70, No. 141/Monday, July 25, 2005/Notices
    42546 Federal Register / Vol. 70, No. 141 / Monday, July 25, 2005 / Notices awpetition.htm/. In addition, an docket. When a document is selected FEDERAL TRADE COMMISSION electronic version of the public docket from the index list in EPA Dockets, the is available through EPA’s electronic system will identify whether the Granting of Request for Early public docket and comment system, document is available for viewing in Termination of the Waiting Period EPA Dockets. You may use EPA Dockets EPA’s electronic public docket. Under the Premerger Notification rules at http://www.epa.gov/edocket/ to Although not all docket materials may submit or view public comments, access be available electronically, you may still Section 7A of the Clayton Act, 15 the index listing of the contents of the access any of the publicly available U.S.C. 18a, as added by Title II of the official public docket, and to access docket materials through the docket Hart-Scott-Rodino Antitrust those documents in the public docket facility identified in Unit I.B.1. EPA Improvements Act of 1976, requires that are available electronically. intends to work towards providing persons contemplating certain mergers Although not all docket materials may electronic access to all of the publicly or acquisitions to give the Federal Trade be available electronically, you may still available docket materials through Commission and the Assistant Attorney access any of the publicly available EPA’s electronic public docket. General advance notice and to wait docket materials through the docket II. What Action is the Agency Taking? designated periods before facility identified in Unit I.B.1.
    [Show full text]
  • Patentes, Desenhos Industriais, Contratos, Programas De Computador, Indicações Geográficas, Topografia De Circuito Integrado
    PATENTES, DESENHOS INDUSTRIAIS, CONTRATOS, PROGRAMAS DE COMPUTADOR, INDICAÇÕES GEOGRÁFICAS, TOPOGRAFIA DE CIRCUITO INTEGRADO o REVISTA DA PROPRIEDADE INDUSTRIAL N 2152 03 de Abril de 2012 SEÇÃO I REPÚBLICA FEDERATIVA DO BRASIL Presidente Dilma Roussef MINISTÉRIO DO DESENVOLVIMENTO, INDÚSTRIA E COMÉRCIO EXTERIOR Ministro do Desenvolvimento, Indústria e Comércio Exterior Fernando Pimentel INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL PRESIDENTE Fax: (31) 3291-5449 Tel.: (27) 3235-7788 Jorge de Paula Costa Ávila Horário de Atendimento: 10h às 16h30 Fax: (27) 3315-9823 Horário de Atendimento: 10h às 16h30 VICE-PRESIDENTE Ademir Tardelli PARANÁ Chefe: Renee Fernando Senger CHEFE DE GABINETE e-mail: [email protected] Goiás Josefina Sales de Oliveira Rua Marechal Deodoro, 344, 16º andar Responsável: Rosemar Rodrigues de Oliveira Marinari Edifício Atalaia, Centro, Curitiba - PR JUNTA COMERCIAL DO ESTADO DE GOIÁS DIRETORIA DE COOPERAÇÃO PARA O Rua 206 - Esquina 259 - Setor Universitário, Quadra 84, Lt. DESENVOLVIMENTO CEP: 80010-909 Denise Nogueira Gregory Telefone: (41) 3322-4411 5 à 8 Goiânia – GO CEP:74640-310 Horário de Atendimento: 10h às 16h30 Tel.: (62) 3202-2246, 3202-2262, 3261-4833 Ramal: 279 PROCURADORIA FEDERAL no INPI Horário de Atendimento: 8h às 18h Mauro Sodré Maia RIO GRANDE DO SUL DIRETORIA DE PATENTES Chefe: Maria Isabel de Toledo Andrade Cunha Maranhão Julio César Castelo Branco Reis Moreira e-mail: [email protected] Responsável: Déa Lourdes Furtado de Oliveira Secretaria de Estado da Indústria e Comércio DIRETORIA DE MARCAS e-mail: [email protected] Vinicius Bogéa Câmara Av. José de Alencar, 521 – Cobertura 902 – Bairro Menino Av. Carlos Cunha s/n° - sala 210 Jesus.
    [Show full text]
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]
  • SCHEDULE 14A (RULE 14A-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(A) of the Securities Exchange Act of 1934 (Amendment No
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant È Filed by a Party other than the Registrant ‘ Check the appropriate box: ‘ Preliminary Proxy Statement. ‘ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2)). È Definitive Proxy Statement. ‘ Definitive Additional Materials. ‘ Soliciting Material Pursuant to §240.14a-12. pSivida Corp. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): È No fee required. ‘ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: ‘ Fee paid previously with preliminary materials. ‘ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. (1) Amount Previously Paid: (2) Form, Schedule or Registration Statement No.: (3) Filing Party: (4) Date Filed: 400 Pleasant Street Watertown, MA 02472 United States October 25, 2012 Dear Fellow Stockholders, It is our pleasure to invite you to this year’s Annual Meeting, which will be held on December 14, 2012 at 10:00 a.m.
    [Show full text]
  • The Influence of Organizational Capacity and Environmental Dynamism on the First Move–Performance Relationship Vera L
    Florida State University Libraries Electronic Theses, Treatises and Dissertations The Graduate School 2006 The Influence of Organizational Capacity and Environmental Dynamism on the First Move–Performance Relationship Vera L. Street Follow this and additional works at the FSU Digital Library. For more information, please contact [email protected] THE FLORIDA STATE UNIVERSITY COLLEGE OF BUSINESS THE INFLUENCE OF ORGANIZATIONAL CAPACITY AND ENVIRONMENTAL DYNAMISM ON THE FIRST MOVE–PERFORMANCE RELATIONSHIP By VERA L. STREET A Dissertation submitted to the Department of Management in partial fulfillment of the requirements for the degree of Doctor of Philosophy Degree Awarded: Fall Semester, 2006 The members of the Committee approve the dissertation of Vera L. Street defended on August 8, 2006. _______________________________ Bruce T. Lamont Professor Directing Dissertation _______________________________ Susan S. Fiorito Outside Committee Member _______________________________ Jack Fiorito Committee Member _______________________________ K. Michele Kacmar Committee Member _______________________________ Pamela L. Perrewé Committee Member Approved: _____________________________ Caryn Beck-Dudley Dean, College of Business The Office of Graduate Studies has verified and approved the above named committee members. ii This dissertation is dedicated to my husband, my teacher, my inspiration, and my best friend, Marc D. Street. iii ACKNOWLEDGEMENTS I would like to thank my dissertation chair, Bruce Lamont, for taking me under his wing and believing in me. Many thanks go to my other committee members as well. Thanks to Micki Kacmar for all the knowledge and advice you imparted to me both in and out of class, thanks for your constant support, and thanks for staying with me across the miles. Thanks to Pam Perrewé for your insights and for always helping me to keep things in perspective.
    [Show full text]
  • Manufacturers/Wholesalers Street City ST Zip 454 Life Sciences Branford CT A.L.I Holdings, LLC A.L.I
    Manufacturers/Wholesalers Street City ST Zip 454 Life Sciences Branford CT A.L.I Holdings, LLC A.L.I. Imaging Systems Corp A.L.I. Technologies (International) LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Rd. Bldg. AP6D-1 Abbott Park IL 60064 Abbott Molecular Division Abbott Nutrition Products Division Abbott Pharmaceutical Products Group Abbott Point of Care Division Abbott Vascular Division Abraxis Bioscience, LLC. 11755 Wilshire Blvd., Suite 2000 Los Angeles CA 90025 Access Diabetic Supply, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Acorda Therapeutics, Inc. 15 Skyline Drive Hawthorne NY 10532 Advanced Neuromodulation Systems, Inc. Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Aesculap Implant Systems, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Alaven Pharmaceuticals, LLC 2260 Northwest parkway Suite A Marietta GA 30067 Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 Alkermes, Inc. 88 Sidney Street Cambridge MA 02139 Allen Medical Systems, Inc. Allergan Sales, LLC Allergan USA, Inc. Allergan, Inc. 2525 Dupont Drive Irvine CA 92612 Alpharma Pharmaceuticals, Inc. Alpharma Pharmaceuticals, LLC AMAG Pharmaceuticals, Inc. 100 Hayden Avenue Lexington MA 02421 AMATECH Corporation American Medical Distributors, Inc. 100 New Highway N Amityville NY 11701 American Medical System,
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0157420 A1 Schneider (43) Pub
    US 2012O157420A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0157420 A1 Schneider (43) Pub. Date: Jun. 21, 2012 (54) TREATMENT AND PREVENTION OF A 6LX 3L/505 (2006.01) SECONDARY INTURY AFTER TRAUMA OR A6IP 29/00 (2006.01) DAMAGE TO THE CENTRAL NERVOUS A6II 3/47 (2006.01) SYSTEM A6IP 25/00 (2006.01) A6IP3/06 (2006.01) (76) Inventor: Eric B Schneider, Glen Arm, MD A6IP 9/00 (2006.01) (US) A6IP 25/22 (2006.01) A6IP 25/24 (2006.01) (21) Appl. No.: 13/392,371 A63L/366 (2006.01) A6II 3/40 (2006.01) (22) PCT Filed: Aug. 31, 2010 (52) U.S. Cl. ......... 514/171; 514/460, 514/419:514/510; (86). PCT No.: PCT/US 10/472O6 514/277; 514/275: 514/423: 514/311 S371 (c)(1), (57) ABSTRACT (2), (4) Date: Feb. 24, 2012 A method of administering one or multiple medications to human patients with CNS injury through oral or parenteral Related U.S. Application Data (including transdermal, intravenous, Subcutaneous, intra (60) Provisional application No. 61/238,453, filed on Aug. muscular) routes. Inflammatory and immunological pro 31, 2009. cesses have been shown to cause secondary damage to CNS s tissues in individuals with acute CNS injury. The present O O invention administers one or more of the following medica Publication Classification tions, which have properties that mitigate the inflammatory (51) Int. Cl. and immunological processes that lead to secondary CNS A6 IK3I/56 (2006.01) damage, via trans-dermal absorption: a statin compound A6 IK 3/405 (2006.01) (e.g., a HMG-CoA reductase inhibitor), a progesterone com A6 IK 3L/25 (2006.01) pound, or a cholinesterase inhibiting compound, among oth A6 IK 3/448 (2006.01) ers, either alone or in combination with other compounds.
    [Show full text]
  • Advanced Sterilization Products Alpharma Pharmaceuticals
    Manufacturers/Wholesalers Street City ST Zip Abbott Diabetes Care Abbott Diagnostic Division Abbott Laboratories 100 Abbott Park Rd. Bldg. AP6D-1 Abbott Park IL 60064 Abbott Molecular Abbott Nutrition Abbott Pharmaceutical Products Group Abbott Point of Care Abbott Spine Abbott Vascular Abraxis Bioscience, LLC. 11755 Wilshire Blvd., Suite 2000 Los Angeles CA 90025 Access Diabetic Supply, LLC Acorda Therapeutics, Inc. 15 Skyline Drive Hawthorne NY 10532 Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Advanced Medical Optics, Inc. 1700 E. St. Andrew Place Santa Anna CA 92705 Advanced Neuromodulation Systems, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Agencourt Bioscience Corporation Alcon Laboratories, Inc. 6201 South Freeway Fort Worth TX 76134 Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 Alkermes, Inc. 88 Sidney Street Cambridge MA 02139 Allergan American, LLC. Allergan Holdings, Inc, Allergan Puerto Rico Holdings, Inc. Allergan Sales Allergan Sales Puerto Rico, Inc. Allergan Specialty Therapeutics, Inc. Allergan USA, Inc. Allergan, Inc. 2525 Dupont Drive Irvine CA 92612 Allscripts, LLC. 2401 Commerce Drive Libertyville IL 60048 Alpharma Pharmaceuticals, LLC 1 New England Ave Piscataway NJ 08854 American Medical System, Inc 10700 Bren Road West Minnetonka MN 55343 Ameridose, LLC. 50 Fountain Street Framingham MA 01702 Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320 Amgen, USA AMO Sales and Service, Inc. Amphastar Pharmaceuticals, Inc. 11570 Sixth St. Rancho Cucamnga CA 91730 AMS- AMS Innovation Center 3070 Orchard Drive San Jose CA 95134 AMS Sales Corporation 10700 Bren Road West Minnetonka MN 55343 Amylin Pharmaceutical, Inc. 9360 Towne Center Drive San Diego CA 92121 Anda Pharmaceuticals, Inc.
    [Show full text]
  • UR-Coeus Sponsor List
    UR-Coeus Sponsor Table (alphabetical by sponsor name) Sponsor Sponsor Code Sponsor Type 2138 21st Century Medicine CORP Sponsor Type Key 1 3M CORP CORP = Corporate 3803 4S3 Bioscience Inc CORP FED = Federal 5207 A. F. Associates Family Medicine ONFA FND = Foundation 2602 A. P. Pharma CORP IND = Individuals 2 A.L. Mailman Foundation FND NYS = New York State 2023 AA Implant Dentistry Research Foundation ONFA OLG = Other Local Gov't 3 AAA Fnd for Traffic Safety ONFA ONFA = Other Non-Fed Agency 2329 aaiPharma Inc CORP VHA = Voluntary Health Agency 3257 Aamjiwnaang First Nations Community ONFA 5345 Aarhus University Hospital ONFA 3713 Aaron Copland Fund for Music, Inc. ONFA 4 AARP Andrus Fdn FND 3853 AB Sciences CORP 3378 AB Vector, Inc CORP 899 Abbott Diagnostics CORP 3864 Abbott Fund FND 14 Abbott Laboratories CORP 5126 AbbVie, Inc. CORP 5854 Abeona Therapeutics CORP 5063 Abington Medical Specialists ONFA 5331 Abington Memorial Hospital ONFA 2835 ABIOMED, Inc. CORP 3687 Ablation Frontiers CORP 5118 Ablynx NV CORP 2053 ABMRF/Fnd for Alcohol Research ONFA 2171 Abortion Rights Mobilization ONFA 3361 Abraxix BioScience, LLC CORP 4953 Abt Associates, Inc. CORP 5037 Academic Gastrointestinal Cancer Consortium ONFA 15 Academic Med Ctr Cons ONFA 3733 Academic Pediatric Association ONFA 3160 Academy of Orofacial Pain ONFA 2122 Academy of Prosthodontics Foundation ONFA 3663 Acadia Pharmaceuticals, Inc. CORP 3273 Accelerate Brain Cancer Cure ONFA 5584 Acceleron Pharma Inc. CORP 5601 Accelovance, Inc. CORP 5940 Accreditation Council Grad Med Educ ONFA 5832 Accriva Diagnostics CORP 3888 AccuGenomics, Inc. CORP 5656 Acerta Pharma CORP 6101 Acessa Health, Inc.
    [Show full text]